• Health & Medicine

CRT and Bioinvent expand collaboration with University of Southampton scientists to develop new immunotherapy treatments for cancer

Cancer Research Technology and BioInvent International begin a 2-year research collaboration with antibody researchers at the University of Southampton Cancer Research Technology and BioInvent International begin a 2-year research collaboration with antibody researchers at the University of Southampton

30 March 2015

• Science & Technology
• Health & Medicine

The Enemy Within – 50 years of fighting cancer

We look back on the last 50 years of cancer research, where we were, what we've achieved and what's still left to do. We look back on the last 50 years of cancer research, where we were, what we've achieved and what's still left to do.

25 December 2014

• Health & Medicine

Cancer Research UK, Cancer Research Technology and Amgen to trial leukaemia immunotherapy drug in other cancers

Cancer Research UK, Cancer Research Technology and Amgen to trial leukaemia immunotherapy drug in patients with soild tuimours. Cancer Research UK, Cancer Research Technology and Amgen to trial leukaemia immunotherapy drug in patients with soild tuimours.

23 December 2014

• Science & Technology
• Health & Medicine

Crowdfunding cancer research – our latest experiment and how you can help

We've launched three exciting crowdfunding projects with our researchers. Will they receive the money they need? Only you can decide. We've launched three exciting crowdfunding projects with our researchers. Will they receive the money they need? Only you can decide.

14 November 2014

• Science & Technology
• Health & Medicine

NCRI 2014 conference summary - day 3

Here’s our round up from day three of the NCRI cancer conference in Liverpool. Here’s our round up from day three of the NCRI cancer conference in Liverpool.

5 November 2014

• Health & Medicine

Biotherapeutics - a new funding scheme for research

Our latest funding scheme focuses on the emerging field of biotherapeutics – smarter cancer treatments based on cells and biological molecules. Our latest funding scheme focuses on the emerging field of biotherapeutics – smarter cancer treatments based on cells and biological molecules.

21 October 2014

• Health & Medicine

Immunotherapy could stop resistance to radiotherapy

Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment. Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment.

1 October 2014

• Health & Medicine

Calming down immune cells could hold key to melanoma treatment

Immune cells may be responsible for drug resistance in melanoma patients, according to research published in Cancer Discovery. Immune cells may be responsible for drug resistance in melanoma patients, according to research published in Cancer Discovery.

25 September 2014

• Health & Medicine

The big issues affecting lung cancer worldwide

We’ve teamed up with the journal Nature, which today publishes a series of articles that touch on some key areas for lung cancer from across the globe. We’ve teamed up with the journal Nature, which today publishes a series of articles that touch on some key areas for lung cancer from across the globe.

11 September 2014

• Health & Medicine
• Science & Technology

New immunotherapy drugs hit the headlines - how do they work?

In the light of continued media attention, we explain the science behind two exciting new types of immunotherapy drug, called PD-1 and PD-L1 blockers. In the light of continued media attention, we explain the science behind two exciting new types of immunotherapy drug, called PD-1 and PD-L1 blockers.

2 June 2014

• Health & Medicine

Promising results in phase 1 trial lead immatics to continue work on vaccine (IMA950) for glioblastoma

A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a Cancer Research UK trial. A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a Cancer Research UK trial.

23 April 2014